MEP1908A - Gaboxadol for treating depression and other affective disorders - Google Patents

Gaboxadol for treating depression and other affective disorders

Info

Publication number
MEP1908A
MEP1908A MEP-19/08A MEP1908A MEP1908A ME P1908 A MEP1908 A ME P1908A ME P1908 A MEP1908 A ME P1908A ME P1908 A MEP1908 A ME P1908A
Authority
ME
Montenegro
Prior art keywords
gaboxadol
treating depression
affective disorders
pharmaceutical composition
relates
Prior art date
Application number
MEP-19/08A
Other languages
Bosnian (bs)
Inventor
Connie Sanchez
Bjarke Ebert
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP1908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Priority claimed from PCT/DK2004/000459 external-priority patent/WO2004112786A2/en
Publication of MEP1908A publication Critical patent/MEP1908A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
MEP-19/08A 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders MEP1908A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
MEP1908A true MEP1908A (en) 2010-02-10

Family

ID=58707228

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-19/08A MEP1908A (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders
MEP-2008-19A ME00030B (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-19A ME00030B (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Country Status (10)

Country Link
KR (1) KR20060025192A (en)
AR (1) AR047550A1 (en)
CA (2) CA2692334A1 (en)
CL (2) CL2004001607A1 (en)
EA (1) EA200600101A1 (en)
IS (1) IS8138A (en)
ME (2) MEP1908A (en)
NO (1) NO20060229L (en)
RS (1) RS20050911A (en)
TW (1) TW200509918A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
KR20060025192A (en) 2006-03-20
AR047550A1 (en) 2006-01-25
CL2004001607A1 (en) 2005-05-27
CL2010000166A1 (en) 2010-07-02
CA2692334A1 (en) 2004-12-29
CA2529805A1 (en) 2004-12-29
RS20050911A (en) 2007-08-03
NO20060229L (en) 2006-01-16
TW200509918A (en) 2005-03-16
IS8138A (en) 2005-11-21
ME00030B (en) 2010-06-10
EA200600101A1 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
TW201713640A (en) Bruton's tyrosine kinase inhibitors
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
CL2008003407A1 (en) Substituted heterobicyclo aryl- and heteroarylcarbonyl derivative compounds; pharmaceutical composition; preparation procedure; and its use in the treatment and / or prevention of metabolic disorders, mediated by the inhibition of the enzyme hsd-1.
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
MX2009010960A (en) Heterocyclic compounds and their methods of use.
MX359668B (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders.
MX2010000098A (en) Polycyclic guanine derivatives and use thereof.
MX368459B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
TW200745122A (en) New compounds I
TW200736227A (en) New compounds III
MX2009013126A (en) New compounds 892.
MX2007006042A (en) Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
UA90656C2 (en) Gaboxadol for treating depression
MEP1908A (en) Gaboxadol for treating depression and other affective disorders
WO2009158387A3 (en) Compositions, formulations, and methods for preventing and/or treating physical effects of alcohol consumption
TW200745133A (en) New compounds II
MY142082A (en) Substituted pyrroles, compositions containing them, method of manufacture and use
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2009105218A3 (en) Propiophenone derivatives
CL2009001113A1 (en) Compounds derived from 4,5-diarylpyrrole-2-carboxamide; procedure for preparing these; pharmaceutical composition comprising them; use in the treatment and / or prevention of psychiatric disorders, substance dependence, among others.